Search
EHA-SLCH Hematology Tutorial on Myeloid Malignancies and MDS
Dates: February 8-9, 2019
Location: Colombo, Sri Lanka
Chairs: G Ossenkoppele, V Gunawardena, HW Goonasekera
After a successful first edition in 2017, EHA is organizing the second two-day tutorial in close collaboration with the Sri Lanka College of Haematologists (SLCH) on "Myeloid malignancies and MDS".…
1st joint EHA – Balkan Hematology Day, a meeting of true regional commitment
1st joint EHA – Balkan Hematology Day
Friday, October 11, 2019 | Pravets, Bulgaria
Meeting Chairs:
Prof Gert Ossenkoppele, Chair EHA Education Committee
Prof Gianluca Gaidano, Chair EHA Global Outreach Program Unit
Prof Margarita Guenova, Representative Balkan Societies
On Friday, October 11th the European Hematology Association (EHA)…
Press Release: Economic burden of blood disorders in EU is €23 billion
The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.
Read morePublications
Experience With IVDR Implementation in Three Diagnostic Laboratories: Messages to EU Health Institutions, Diagnostic Healthcare Payers, and Authorities
Lubbers BR, Dombrink I, Kalina T, Hofmans M, Bruun MS, Stanworth SJ, Béné MC, Döhner K, Brüggemann M, Macintyre E, van Dongen JJM.…
EHA Guidelines by Topic
AL Amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022)
Anemia
Recommendations regarding splenectomy in hereditary hemolytic anemias (2017)
Management of…
Previous winners, 2012–2022
2022 winners
Alexandre Fagnan
Junior Research Grant 2022
Deciphering the chromatin remodeling mechanism mediated by GATA2 ZnF1 mutations in AML
Samuele Ferrari
Junior Research Grant 2022
Innovative targeted base editing strategies for gene correction of WHIM syndrome
Lars Velten
Advanced Research Grant 2022
The role of the DNA methylation…
First randomized evidence for kinase inhibitor activity in acute myeloid leukemia
Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- »